Transfer of multiantigen-specific T cells after allogeneic stem cell transplantatio
- Conditions
- Patients with a haematological malignancy who are planned to undergo an allogeneic stem cell transplantation
- Registration Number
- NL-OMON25777
- Lead Sponsor
- eiden University Medical Center (LUMC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 17
Inclusion Criteria
Age 18-75 years
- Planned T cell depleted allo-SCT for one of these diagnoses:
Exclusion Criteria
- Disease specific treatment foreseen in the first 6 months after SCT
- Life expectation < 6 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the efficacy of the transfer of multiantigen specific T cells by measuring the<br>appearance or expansion (if antigenic specific donor derived cells are already present in the circulation of the patient at time of infusion) of antigen specific donor derived T cells during eight weeks after the infusion of donor derived multi antigen specific T cells.
- Secondary Outcome Measures
Name Time Method To assess the feasibility and safety (toxicity) of the administration of donor derived multi antigen specific T cells early after T cell depleted allo-SCT.